Cardiovascular outcome trials have shown remarkable cardioprotective effects of these selective SGLT2 inhibitors showing reduced mortality from cardiovascular causes, all-cause death and hospitalization for heart failure in T2DM patients with established cardiovascular diseases [21–23]. Here, SLC5A2 is linked to heart failure.